tbuckley/cabot-search huggingface dataset:
Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)
Authors: Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Richard Levy, Edward Bradley, William Garrett, Kris Vaddi, Nancy Contel, Victor Sandor, Reid Michael Huber, Lee P. Schacter, Elisa Rumi, Elisabetta Gattoni, Elisabetta Antonioli, Lisa Pieri, Mario Cazzola, Hagop Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood (2010)
MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma
Authors: Roberta Zappasodi, Alessandra Cavanè, Marilena V Iorio, Monica Tortoreto, Giusi Ruggiero, Michele Magni, Carmelo Carlo-Stella, Elda Tagliabue, Franco Zunino, Carlo M. Croce, Alessandro M. Gianni, Massimo Di Nicola
Journal: Blood (2011)
In Vitro Knock-Down of Myh9 Leads to a Myh9-Related Disorder Phenotype in Human Megakaryocytes.
Authors: Yolande Chen, Siham Boukour, Monia Romdhane, Ababacar Seye, Olivier Bluteau, Larissa Lordier, Yunhua Chang, Anne Galy, Rémi Favier, Paquita Nurden, Hana Raslova, William Vainchenker, Najet Debili
Journal: Blood (2009)
QLIF-10. FAMILY CAMP: A MULTI-DISCIPLINARY, HOLISTIC INTERVENTION FOR BRAIN TUMOR PATIENTS AND THEIR FAMILIES
Authors: Emelia Barani, Margaretta Page, Mary. P Lovely, Abigail Marks, Amanda Lamarre, Judy Patt, Susan Chang, Jennifer Clarke
Journal: Neuro-Oncology (2016)

A brain tumor diagnosis is a devastating and life-altering event that impacts the entire family. Families experience radical change of roles due to cognitive, physical, and emotional changes resulting from the illness. “Family Camp” was a targeted psychosocial intervention to create a safe environment that would provide families with children respite from daily burdens and connect them with similar others. In 2014, a multi-disciplinary team established a weekend camp. Staff included artists, body workers, psychologists, “camp counselors”, doctors, nurses, social workers, who are members of their healthcare team, and community volunteers. Interventions included counseling, community building, and educational sessions. Communication strategies were suggested to enhance family communication. Opportunities for art, singing, games, and rest were provided. Anxiety, stress, depression, coping, and values-based living were measured pre and post camp using DASS21, CES-D, Brief Cope Inventory, Values Based Living, and surveys. 11 families (22 adults) attended camp; 15 adults remained the entire duration. A paired sample t-test was conducted to compare scores before and after camp on a variety of outcomes. On the DASS21 patients (n=7) reported statistically significant decreases in the axes of depression and stress; p= 0.038 and 0.0077 and caregivers (n=8) reported statistically significant decreases in depression and anxiety; p=0.02 and 0.017. This was also reflected on the CES-D; p=0.021. Subjective assessments were consistent with these observations, and most felt that the experience made them closer as a family. A multi-disciplinary program focused on patients’ families improves psycho-social stressors. Data suggest that support programs designed for entire families may be an important intervention that improves quality-of-life and perception of the “illness” experience. Sustainability of observed benefits are unknown, but serial interventions are likely important in this patient population with variable disease trajectories.
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)
Authors: Jeanelle King, Javier de la Cruz, Jose Lutzky
Journal: Journal for ImmunoTherapy of Cancer (2017)

<h3>Background</h3> CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is to regulate the amplitude of the early stages of T-cell activation.1 Ipilimumab, a CTLA-4 blocking antibody, has been widely used for the treatment of patients with high risk and metastatic melanoma. Given its mechanism of action and consequent immune activation, the side effect profile of this drug greatly differs from that of standard cytotoxic chemotherapy. Adverse events are from the most part immune-mediated, ranging from the more common, such as rash and fatigue, to the less common, such as immune endocrinopathy and colitis. <h3>Case presentation</h3> We describe a case of immune-mediated thrombotic thrombocytopenic purpura (TTP) in a 68&nbsp;year-old woman with high risk, stage III melanoma occurring after 3&nbsp;cycles of adjuvant treatment with ipilimumab as part of a clinical trial. <h3>Conclusion</h3> The range of immune-mediated adverse events during treatment with ipilimumab is wide and varied and clinicians should have a high degree of suspicion when managing these patients.
ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura
Authors: Giuseppe Bettoni, Luca A Lotta, Dario Consonni, Dino FA Motti, Roberta Palla, Carla Valsecchi, Gloria Casoli, Andrea Rovati, Michele Pizzuti, Flora Peyvandi
Journal: Blood (2010)
Patients with borderline resectable colorectal cancer liver metastases (CLM): preliminary safety and activity of perioperative triplet chemotherapy plus bevacizumab (bev)
Authors: A. Mennitto, C. Cotsoglou, M. Caporale, M. Scotti, R. Berenato, J. Coppa, M. Di Bartolomeo, M. Milione, I. Bossi, F. de Braud, V. Mazzaferro, F. Pietrantonio
Journal: Annals of Oncology (2016)
Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Sikander Ailawadhi, Francisco J. Hernandez-Ilizaliturri, Loretta Miner, Zale P. Bernstein, Asher Chanan-Khan, Kena C. Miller, Alice Mohr, Petr Starostik, Myron S. Czuczman, Swaminathan Padmanabhan
Journal: Blood (2007)
Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.
Authors: Nina Undevia, Cara C. Tigue, Dennis P. West, June M. McKoy, Beatrice J. Edwards, David A. Dorr, Dennis W. Raisch, Charles L. Bennett
Journal: Blood (2007)
P01.09 Epilepsy associates with decreased HIF1-α/STAT5B and SRF signaling in glioblastoma
Authors: S. Berendsen, W. G. M. Spliet, M. Geurts, W. Van Hecke, T. Seute, T. J. Snijders, E. H. Bell, A. Chakravarti, P. A. Robe
Journal: Neuro-Oncology (2016)
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed AL Amyloidosis: Experience of Two Centers in Canada
Authors: Hatem Alahwal, Kevin W. Song, Peter Duggan, Heather J. Sutherland, Paola Neri, Raewyn Broady, Nizar J. Bahlis, Victor Jimenez-Zepeda
Journal: Blood (2016)
TMOD-07. CELLULAR ORIGINS OF GLIOBLASTOMA: LESSONS FROM MOUSE MODELS
Authors: Sheila Alcantara Llaguno, Zilai Wang, Daochun Sun, Jian Chen, Alicia Pedraza, Jing Xu, Euiseok Kim, Kimmo Hatanpaa, Jack Raisanen, Dennis Burns, Jane Johnson, Luis Parada
Journal: Neuro-Oncology (2016)

A central question in glioblastoma research is the identity of the tumor-initiating cell and its contribution to the malignant phenotype and genomic state. We systematically examined the potential of adult CNS progenitors, and immature and mature neurons to induce fully penetrant glioblastoma using lineage-specific inducible cre mice to inactivate the tumor suppressors Nf1, Trp53 and Pten. Adult CNS progenitors give rise to phenotypically and molecularly distinct tumor subtypes, which, despite histologic identity as glioblastoma, are separable based on the lineage of the cell of origin. Mutations induced in adult neurons do not lead to tumor development. These studies identify adult lineage-restricted CNS progenitors but not neurons as tumor-initiating cells and point to the cell of origin as a major determinant of glioblastoma subtype diversity.
Neuronal/Mitochondrial Nitric Oxide Synthase Homologous Deletion Recombinant Negative Mice (NOS1 −/−) Long-Term Bone Marrow Cultures (LTBMCs) Demonstrate Increased Longevity and Radioresistance of Derived Cell Lines.
Authors: Michael W. Epperly, Joel S. Greenberger, Shaonan Cao, Darcy Franicola, Hongmei Shen, Emily E. Greenberger, Laura D. Epperly, Xicheng Zhang
Journal: Blood (2006)
Ex-Vivo Characterization of Polyclonal Memory CD8+ T-Cell Responses to PRAME-Specific Peptides in Patients with Acute Leukemia and Chronic Myeloid Leukemia
Authors: Katayoun Rezvani, Agnes S. M. Yong, Abdul Tawab, Behnam Jafarpour, Rhoda Eniafe, Stephan Mielke, Bipin N. Savani, Keyvan Keyvanfar, Li Yixin, Roger Kurlander, A. John Barrett
Journal: Blood (2008)
PDCT-09. HYPERMUTATION AND NEOANTIGEN FORMATION IS DIAGNOSTIC AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT BRAIN TUMORS
Authors: Brittany Campbell, Eric Bouffet, Valerie Larouche, Gary Mason, Alyssa Reddy, Michael Osborne, Vanan Magimairajan, Daniele Merico, Richard de Borja, Brian Chung, Melissa Galati, Melyssa Aronson, Carol Durno, Joerg Krueger, Vanja Cabric, Nataliya Zhukova, Vijay Ramaswamy, Roula Farah, Samina Afzal, Michal Yalon, Gidi Rechavi, Michael Walsh, Dvir Rina, Elhasid Ronit, Michael Sullivan, Jordan Hansford, Andrew Dodgshun, Nancy Klauber-Demore, Lindsay Peterson, Sunil J. Patel, Scott M. Lindhorst, Jeffrey Atkinson, Rachel Laframboise, Zane Cohen, Peter Dirks, Michael Taylor, David Malkin, Steffen Albrecht, Roy Dudley, Nada Jabado, Cynthia Hawkins, Adam Shlien, Uri Tabori
Journal: Neuro-Oncology (2016)
Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.
Authors: Paul La Rosée, Susanne Holm-Eriksen, Thomas Ernst, Heiko König, Philipp Erben, Martin Müller, Thomas Schenk, Michael Emig, Anja Binckebanck, Lydia Wunderle, Leila Alland, Peter Schuld, Rüdiger Hehlmann, Oliver G. Ottmann, Andreas Hochhaus
Journal: Blood (2005)
Phase 1/2a study of RX-5902 in advanced solid tumors (ST): An orally bioavailable inhibitor of phosphorylated P68 and modulator of &amp;bgr;-catenin nuclear translocation
Authors: S.G. Eckhardt, W.L. Gluck, M. Gutierrez, C. Peterson, R. Mazhari, E. Benaim
Journal: Annals of Oncology (2016)
The JAK1/2 Inhibitor Ruxolitinib Kills Malignant Plasma Cells and Is Synergistic with PI3K and mToR Inhibitors
Authors: Renate Burger, Tim Bugdahn, Matthias Staudinger, Anna Lena Michaelis, Matthias Peipp, Andreas Guenther, Martin Gramatzki
Journal: Blood (2012)
IMST-11. DOWNREGULATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR TYPE 1 MEDIATES BONE MARROW T-CELL SEQUESTRATION IN PATIENTS AND MICE WITH GLIOBLASTOMA
Authors: Pakawat Chongsathidkiet, S. Harrison Farber, Karolina Woroniecka, Aladine A. Elsamadicy, Xiuyu Cui, Peter Fecci
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM), the most common and universally lethal primary brain tumor, is amongst the most immunosuppressive of solid tumors. Despite rarely metastasizing outside the CNS, GBM elicits profound T-cell lymphopenia and systemic T-cell dysfunction. Lymphopenia in GBM patients is frequently attributed to therapies incorporating temozolomide, dexamethasone, and radiation. We reveal, however, that even treatment-naïve patients frequently demonstrate dramatically diminished T-cell counts, including AIDS-level CD4 counts of 200 cells/μL or below. Patients simultaneously exhibit lymphoid organs retraction, averaging a 30% reduction in spleen volume. While disappearing from these compartments, T-cells instead re-appear in large numbers in the bone marrow. Patients can harbor up to 20-fold higher T-cell counts in marrow compared to blood. These findings are recapitulated in murine GBM models, where spleens and thymuses contract severely in size, while marrow T-cell counts increase 3 to 5-fold. Adoptive transfer experiments suggest that T-cells are sequestered in marrow after acquiring alterations in the intracranial tumor-bearing state. We uncover the requisite T-cell alteration to be downregulation of surface sphingosine-1-phosphate receptor type 1 (S1P1). Pharmacologically induced S1P1 loss on T-cells is sufficient to elicit their immediate sequestration in GBM-bearing mice, while genetic stabilization of the receptor abrogates the phenomenon. These findings characterize not only GBM, but various other malignancies (lung, melanoma, breast), yet only when these tumors are implanted intracranially. Importantly, abrogating sequestration alone conveys a survival benefit in murine GBM with accompanying increased numbers of activated tumor-infiltrating lymphocytes. We, therefore, advance here a novel mode of T-cell dysfunction in cancer contributed specifically by the intracranial environment: S1P1-mediated bone marrow T-cell sequestration. This finding likewise suggests that the brain harbors unique mechanisms for preventing T cell entry into the CNS, mechanisms which are usurped by tumors to favor immune escape. More broadly, such mechanisms are anticipated to hold numerous implications for basic CNS immunology.
Metastatic descending colon cancer in an elderly man that was controlled with a combination chemotherapy after TAS-102
Authors: Atsushi Naganuma, Daisuke Uehara, Yuta Watanuki, Keisuke Shiina, Haruka Yoshida, Eri Hayashi, Sanae Uehara, Takashi Hoshino, Tomohiro Kudo, Hiroshi Ishihara
Journal: Annals of Oncology (2016)
Using Patient-Centered Care After a Prenatal Diagnosis of Trisomy 18 or Trisomy 13
Authors: Shelly Haug, Mitchell Goldstein, Denise Cummins, Elba Fayard, T. Allen Merritt
Journal: JAMA Pediatrics (2017)

Patient-centered care (PCC) has been advocated by the Institute of Medicine to improve health care in the United States. Four concepts of PCC align with clinical ethics principles and are associated with enhanced patient/parent satisfaction. These concepts are dignity and respect, information sharing, participation, and collaboration. The objective of this article is to use the PCC approach as a framework for an extensive literature review evaluating the current status of counseling regarding prenatal diagnosis of trisomy 18 (T18) or trisomy 13 (T13) and to advocate PCC in the care of these infants.Extensive availability of prenatal screening and diagnostic testing has led to increased detection of chromosomal anomalies early in pregnancy. After diagnosis of T18 or T13, counseling and care have traditionally been based on assumptions that these aneuploidies are lethal or associated with poor quality of life, a view that is now being challenged. Recent evidence suggests that there is variability in outcomes that may be improved by postnatal interventions, and that quality-of-life assumptions are subjective. Parental advocacy for their infant's best interest mimics this variability as requests for resuscitation, neonatal intensive care, and surgical intervention are becoming more frequent.With new knowledge and increased parental advocacy, physicians face ethical decisions in formulating recommendations including interruption vs continuation of pregnancy, interventions to prolong life, and choices to offer medical or surgical procedures. We advocate a PCC approach, which has the potential to reduce harm when inadequate care and counseling strategies create conflicting values and uncertain outcomes between parents and caregivers in the treatment of infants with T18 and T13.
FDA Regulation of Prescription Drugs
Authors: Audrey L. Gassman, Christine P. Nguyen, Hylton V. Joffe
Journal: New England Journal of Medicine (2017)

Over the past 5 years, the FDA has approved 182 new drugs. This overview explains the FDA's drug-approval process, including its approach to benefit–risk assessment, drug labeling, risk evaluation and mitigation strategies, and postmarketing surveillance.
ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer
Authors: E.C. James, J. Hook, S. Stenning, A. Cook, C. Coyle, J. Petrie, R. Kaplan, I. McNeish, T. Perren, R. Naik, S. Banerjee, J.A. Ledermann, A. Clamp
Journal: Annals of Oncology (2016)
3-Nitrotyrosine in Sera of Patients with Myelodysplastic Syndromes, a Preliminary Study
Authors: Jaromir Novak, Jiri Suttnar, Leona Chrastinova, Jana Stikarova, Alzbeta Hlavackova, Ondrej Pastva, Roman Kotlin, Jaroslav Cermak, Jan E Dyr
Journal: Blood (2014)
High Titer Lentivector from a Stable Lenti-Producer Efficiently Corrects CD34+ Hematopoietic Stem Cells from Patients with p47phox-Deficient Chronic Granulomatous Disease
Authors: Uimook Choi, Narda Theobald, Throm E Robert, John Gray, David J. Rawlings, Brian P. Sorrentino, Harry Malech, Suk See De Ravin
Journal: Blood (2015)
Safety Profile of Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) from Post-Authorization Safety Surveillance (PASS) Program.
Authors: Huong Luu, Gerald Spotts, Hartwig Gajek, Alex Kriukov, Roger Berg, Darby Stephens, Kerry Barker, Bruce Ewenstein
Journal: Blood (2007)
YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor–Induced Activation of the PI3K Pathway
Authors: Chao Wang, Chao Gu, Kang Jin Jeong, Dong Zhang, Wei Guo, Yiling Lu, Zhenlin Ju, Nattapon Panupinthu, Ji Yeon Yang, Mihai (Mike) Gagea, Patrick Kwok Shing Ng, Fan Zhang, Gordon B. Mills
Journal: Cancer Research (2017)

Abstract The transcription regulators YAP and TAZ function as effectors of the HIPPO signaling cascade, critical for organismal development, cell growth, and cellular reprogramming, and YAP/TAZ is commonly misregulated in human cancers. The precise mechanism by which aberrant YAP/TAZ promotes tumor growth remains unclear. The HIPPO tumor suppressor pathway phosphorylates YAP and TAZ, resulting in cytosolic sequestration with subsequent degradation. Here, we report that the PI3K/AKT pathway, which is critically involved in the pathophysiology of endometrial cancer, interacts with the HIPPO pathway at multiple levels. Strikingly, coordinate knockdown of YAP and TAZ, mimicking activation of the HIPPO pathway, markedly decreased both constitutive and growth factor–induced PI3K pathway activation by decreasing levels of the GAB2 linker molecule in endometrial cancer lines. Furthermore, targeting YAP/TAZ decreased endometrial cancer tumor growth in vivo. In addition, YAP and TAZ total and phosphoprotein levels correlated with clinical characteristics and outcomes in endometrial cancer. Thus, YAP and TAZ, which are inhibited by the HIPPO tumor suppressor pathway, modify PI3K/AKT pathway signaling in endometrial cancer. The cross-talk between these key pathways identifies potential new biomarkers and therapeutic targets in endometrial cancer. Cancer Res; 77(7); 1637–48. ©2017 AACR.
Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer
Authors: I. Chau, S.-E. Al-Batran, A. Barzi, A.M. Liepa, Z. Cui, Y. Hsu, S. Chin
Journal: Annals of Oncology (2016)
IMST-43. A TOXICITY ASSESSMENT OF BRAIN RADIATION AND FINGOLIMOD IN AN ANIMAL MODEL OF TREATMENT-RELATED LYMPHOPENIA
Authors: Anna F. Piotrowski, Dvone Jackson
Journal: Neuro-Oncology (2016)

Standard radiation, temozolomide and glucocorticoids cause severe and long- lasting lymphopenia in 40% of patients with malignant gliomas which is associated with inferior survival. As inadvertent irradiation of circulating lymphocytes may contribute to lymphopenia, fingolimod (sphingosine-1 phosphate agonist which sequesters lymphocytes in lymphoid tissues) is being studied as a new intervention to reduce this immunosuppression. Given the profound lymphopenia that may occur from radiation combined with fingolimod, safety was evaluated in a novel model of radiation-related lymphopenia. 10 BALB/c male mice age 7-12 weeks received 4 Gy x 10 fractions of focal brain irradiation using the small animal radiation research platform (SARRP). Half of these animals were given daily intraperitoneal injections of fingolimod 3mg/kg for 4 days prior to the start of radiation and throughout the 2 week course of radiation. Tolerability was assessed by daily observations (body weight, posture, eye movements, activity level) and by blood tests every 4 days (total lymphocyte count [TLC], absolute neutrophil count, hematocrit, platelet count). All mice became severely lymphopenic then quickly recovered to baseline. There was no difference in post-treatment body weight (25.6 vs 23.4 g, p=0.17) or TLC (2.03 vs. 1.96, p=0.84) in animals that received radiation alone compared to radiation plus fingolimod. Other hematologic parameters as well as cageside observations were not statistically different in control versus experimental arms. These transient decreases in TLC are consistent with the effect of radiation alone in our previous studies. This preliminary data demonstrates that adding fingolimod to radiation does not increase toxicity to the mice and has no effect on the previously documented recovery from lymphopenia. Studies are currently underway to determine if this novel approach is also safe in patients with primary brain tumors.
The detection of AR-V7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
Authors: M. Del Re, E. Biasco, S. Crucitta, L. Derosa, E. Rofi, A. Sbrana, A. Farnesi, G. Restante, L. Galli, A. Falcone, G. Jenster, R. van Schaik, R. Danesi
Journal: Annals of Oncology (2016)
P10.02 Retrospective analysis on chemotherapy for pediatric High-Grade Gliomas: the experience at Meyer Children’s Hospital
Authors: M. Lucchesi, S. Scoccianti, M. Guidi, L. Facchini, S. Farina, C. Fonte, C. Favre, L. Genitori, I. Sardi
Journal: Neuro-Oncology (2016)
£9.5bn or “drastic cuts” only way deliver STPs, says BMA
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

The sustainability and transformation plans (STPs),1 set up to improve the quality of care and save £15bn (€17.7bn; $18.8bn) of the £22bn needed across England by 2020, will cost £9.5bn to deliver, the BMA has said in a new analysis.

The costs relate to the infrastructure that is needed to make the savings—such as building projects and investment in community facilities—responses to freedom of information requests submitted by 37 of the 44 footprint areas charged with making the plans have shown.

More than half of the STP footprint areas have told NHS England that they would need more than £100m up front to make changes to …
Screening of patients for clinical trials, the academic and the community perspective
Authors: C. F. Verschraegen, C. Reich, J. Ferguson, P. Schoenfeld
Journal: Journal of Clinical Oncology (2005)

5124 Background: In the US, the percentage of patients (pts) that enroll in adult therapeutic clinical trial is less than 10%. Different barriers have been identified, such as pt willingness, or physician behavior. We looked at two different pt populations who were screened for participation in oncology clinical trials. Methods: All new pts who were seen at UNM CRTC from September 8 and December 15, 2003 (academic population) and most new pts seen at the NM Cancer Care Alliance (NMCCA) from April 21 to December 7, 2004 were included in eight categories for not enrolling in a clinical trial (see table). Results: 502 pts (out of 657 pts seen) at UNM CRTC and 189 pts at the NMCCA had a diagnosis of cancer, and 126 (25%, UNM CRTC) and 46 (24%, NMCCA) were enrolled in a therapeutic clinical trial. Patients did not enroll in a clinical trial for the following reasons: Conclusions: The two main reasons for non participation are lack of protocol availability and lack of interest on the part of the pt or the physician. In a less privately insured pt population (UNM CRTC), more pts declined to participate. More patient education must be planned to improve clinical trial enrollment. The menu of clinical trial must also be carefully chosen to maximize patient enrollment. No significant financial relationships to disclose.